Company Profile
Cayman Pharma was formed in October of 2006 by the merger of two companies with very different geographic origins. Both, however, had unparalleled experience and expertise in Prostaglandin Chemistry. One was Cayman Chemical, a research biochemical company with global recognition as an expert in the field of lipid chemistry. The other was NeraPharm, a company located within the Spolana complex north of Prague since the late 1970s, but only operating as an independent legal entity since 2002. NeraPharm was conceived during the era of Soviet economic domination and central planning. Their goal, which was largely achieved, was to implement independent production of important veterinary prostaglandins for the entire Eastern Bloc. Cayman had its beginnings just a few years later, in 1980. Cayman's vision, also largely accomplished, was to demon
VIEW MORE VIEW LESSProduct List
| Product Name | Synonyms | CAS No. | Grate/Content | Operate |
|---|---|---|---|---|
5-Heptenoic acid,7-[(1R,2R,3R,5S)-2-[(1E,3S)-4-(3-chlorophenoxy)-3-hydroxy-1-buten-1-yl]-3,5-dihydroxycyclopentyl]-,(5Z)-rel- |
5-Heptenoic acid,7-[(1R,2R,3R,5S)-2-[(1E,3R)-4-(3-chlorophenoxy)-3-hydroxy-1-buten-1-yl]-3,5-dihydroxycyclopentyl]-,(5Z)-rel-;5-Heptenoic acid,7-[2-[4-(3-chlorophenoxy)-3-hydroxy-1-butenyl]-3,5-dihydroxycyclopentyl]-,[1α(Z),2β(1E,3R*),3α,5α]-(±)-;5-Heptenoic acid,7-[(1R,2R,3R,5S)-2-[(1E,3R)-4-(3-chlorophenoxy)-3-hydroxy-1-butenyl]-3,5-dihydroxycyclopentyl]-,(5Z)-rel-;rel-(5Z)-7-[(1R,2R,3R,5S)-2-[(1E,3R)-4-(3-Chlorophenoxy)-3-hydroxy-1-buten-1-yl]-3,5-dihydroxycyclopentyl]-5-heptenoic acid;5-Heptenoic acid,7-[2-[4-(3-chlorophenoxy)-3-hydroxy-1-butenyl]-3,5-dihydroxycyclopentyl]-,[1α(Z),2β(1E,3R*),3α,5α]-;Cloprostenol;Oestrophan;Estrophane;Estrofan;Oestrophane;Estrophan;Racemic cloprostenol;(±)-Cloprostenol;DL-Cloprostenol;Clostenol;Cyclix;Juramate;Estroplan;Estromil;Ovuprost;Estrofantin;100786-10-5;53529-41-2;87347-50-0 |
40665-92-7 | Inquiry | |
5-Heptenoic acid,7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]-, 1-methylethylester, (5Z)- |
5-Heptenoic acid,7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]-,1-methylethyl ester,(5Z)-;5-Heptenoic acid,7-[3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]-,1-methylethyl ester,[1R-[1α(Z),2β,3α,5α]]-;UF 021;Rescula;Isopropyl unoprostone;Unoprostone isopropyl ester;13,14-Dihydro-15-keto-20-ethyl-PGF2;13,14-Dihydro-15-keto-20-ethyl-PG F2α isopropyl ester;1044661-14-4 |
120373-24-2 | Inquiry | |
Bimatoprost |
5-Heptenamide,7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]cyclopentyl]-N-ethyl-,(5Z)-;5-Heptenamide,7-[3,5-dihydroxy-2-(3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl]-N-ethyl-,[1R-[1α(Z),2β(1E,3S*),3α,5α]]-;5-Heptenamide,7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-pentenyl]cyclopentyl]-N-ethyl-,(5Z)-;(5Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]cyclopentyl]-N-ethyl-5-heptenamide;Bimatoprost;AGN 192024;Lumigan;Prostamide;Latisse;17-Phenyltrinor-PGF2α ethylamide;267244-98-4 |
155206-00-1 | Inquiry | |
Latanoprost |
5-Heptenoic acid,7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-,1-methylethyl ester,(5Z)-;5-Heptenoic acid,7-[3,5-dihydroxy-2-(3-hydroxy-5-phenylpentyl)cyclopentyl]-,1-methylethyl ester,[1R-[1α(Z),2β(R*),3α,5α]]-;Latanoprost;PhXA 41;XA 41;Xalatan;GAAP Ofteno;(15R)-Latanoprost;Prolatan;(+)-Latanoprost;474944-24-6;144489-49-6 |
130209-82-4 | Inquiry | |
Pentanoic acid,5-[(3aS,4R,5R,6aS)-hexahydro-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyl-1-octen-6-yn-1-yl]-2(1H)-pentalenylidene]-,(5E)- |
Pentanoic acid,5-[(3aS,4R,5R,6aS)-hexahydro-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyl-1-octen-6-yn-1-yl]-2(1H)-pentalenylidene]-,(5E)-;Pentanoic acid,5-[(3aS,4R,5R,6aS)-hexahydro-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyl-1-octen-6-ynyl]-2(1H)-pentalenylidene]-,(5E)-;(5E)-5-[(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyl-1-octen-6-yn-1-yl]-2(1H)-pentalenylidene]pentanoic acid;ZK 36374;Ciloprost;Iloprost;Ilomedin;(1S,2R,3R,5S)-7-[(E)-4-Carboxybutylidene]-2-[(3S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-bicyclo[3.3.0]octane;Endoprost;73873-87-7 |
78919-13-8 | Inquiry | |
Prosta-5,13-dien-1-oicacid, 11,15-dihydroxy-9-oxo-, (5Z,11a,13E,15S)- |
Prosta-5,13-dien-1-oic acid,11,15-dihydroxy-9-oxo-,(5Z,11α,13E,15S)-;5-Heptenoic acid,7-[3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl]-;5-Heptenoic acid,7-[3α-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl]-;(5Z,11α,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid;PGE2;Prostaglandin E2;U 12062;11α,15α-Dihydroxy-9-oxo-5-cis,13-trans-prostadienoic acid;(15S)-Prostaglandin E2;(-)-Prostaglandin E2;11α,15α-Dihydroxy-9-ketoprosta-5,13-dienoic acid;Dinoprostone;Prostin E2;Prepidil;l-Prostaglandin E2;l-PGE2;Minprostin E2;Prostenon;Prostenone;Cervidil;Prostin;Prostin (prostaglandin);Glandin;Prostarmon E;Cerviprost;Propess;Minprositin E2;Enzaprost E;NSC 165560;NSC 196514;Primiprost;Cerviprime;11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid (5Z,11α,13E,15S);5: PN: US20150065431 SEQID: 5 claimed sequence;7-[3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentyl]-5-heptenoic acid |
363-24-6 | Inquiry | |
Prostaglandin E1 |
Prost-13-en-1-oic acid,11,15-dihydroxy-9-oxo-,(11α,13E,15S)-;Cyclopentaneheptanoic acid,3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-,(-)-;Cyclopentaneheptanoic acid,3α-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-;(11α,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid;PGE1;Prostaglandin E1;11α,15(S)-Dihydroxy-9-oxo-13-trans-prostenoic acid;(-)-Prostaglandin E1;l-Prostaglandin E1;11α,15α-Dihydroxy-9-oxo-13-trans-prostenoic acid;Alprostadil;U 10136;Prostandin;l-PGE1;Prostandin 500;Caverject;Alprox TD;Palux;ONO 1608;Lipoprost;Topiglan;SEPA-PGE1;SEPA-alprostadil;SEPA-prostaglandin E1;Minprog;Prostivas;Prostin VR Pediatric;Liple;NSC 165559;Caveject;Vasaprostan;Liprostin;Eglandin;Lipo PGE1;Alprostan;50-83-9;22299-37-2;50865-30-0 |
745-65-3 | Inquiry | |
Prostaglandin E1 ALPHA-cyclodextrin clathrate compound |
Prost-13-en-1-oic acid,11,15-dihydroxy-9-oxo-,(11α,13E,15S)-,compd. with α-cyclodextrin (1:1);α-Cyclodextrin,compd. with (11α,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid (1:1);2,4,7,9,12,14,17,19,22,24,27,29-Dodecaoxaheptacyclo[26.2.2.23,6.28,11.213,16.218,21.223,26]dotetracontane,α-cyclodextrin deriv.;Prostaglandin E1-α-cyclodextrin compd.;PGE1-α-cyclodextrin inclusion compd.;Prostaglandin E1-α-cyclodextrin inclusion compd.;G 511;Alprostadil alfadex;PGE1 α-CD;Tandetoron;93591-00-5 |
93591-00-5 | Inquiry |
CONTACT INFORMATION
Sign In for Details